Melissa Greene, CNM | |
104 Medical Dr, Williamston, NC 27892-2156 | |
(252) 809-6341 | |
Not Available |
Full Name | Melissa Greene |
---|---|
Gender | Female |
Speciality | Advanced Practice Midwife |
Location | 104 Medical Dr, Williamston, North Carolina |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1093714610 | NPI | - | NPPES |
C8684 | Other | NC | MEDCOST |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207V00000X | Obstetrics & Gynecology | 138779 (North Carolina) | Secondary |
367A00000X | Advanced Practice Midwife | 138779 (North Carolina) | Primary |
Mailing Address | Practice Location Address |
---|---|
Melissa Greene, CNM 7100 Commerce Way, Suite 180, Brentwood, TN 37027-2829 Ph: (615) 465-7000 | Melissa Greene, CNM 104 Medical Dr, Williamston, NC 27892-2156 Ph: (252) 809-6341 |
News Archive
ExactCost, Inc., a technology company that provides activity-based costing and performance management software solutions for the healthcare industry, today announced that Memorial Healthcare System, headquartered in Hollywood, Florida, has signed a multi-year license agreement to implement the ExactCost® Cardiovascular Service Line.
The growing number and costs of drugs for rare diseases (orphan drugs) are straining healthcare budgets. Should the NHS continue to pay for them and how will this affect other health services, ask two articles in this week's British Medical Journal (BMJ)?
Too many men don't know their risk for developing prostate cancer, a disease that currently affects more than two million American men. In fact, according to a recent report, 61 percent of men only know "a little" and an additional 20 percent say they know nothing about prostate health. This knowledge gap is of critical importance given that one in six men has a lifetime risk of developing prostate cancer.
For years, scientists have pointed to leptin resistance as a possible cause of obesity. Research led by investigators at the University of Cincinnati (UC) Metabolic Diseases Institute, however, found that leptin action isn't the culprit.
Fero Industries, Inc. is pleased to announce that it has contracted PNP Pharmaceuticals Inc. as the exclusive global manufacturer of Sucanon®, an oral treatment for type-2 diabetes.
› Verified 4 days ago